Palisade Bio Inc. (PALI) News
Filter PALI News Items
PALI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PALI News From Around the Web
Below are the latest news stories about PALISADE BIO INC that investors may wish to consider to help them evaluate PALI as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday! |
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anticipated to commence Phase 1 clinical study in 2024 – Strong financial position with cash to execute on strategy and achieve significant milestones into 2025 Carlsbad, CA, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade |
Palisade Bio to Participate at the Virtual Investor Ask the CEO ConferenceLive moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 2:00 PM |
Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio IncOn September 13, 2023, John Finley, CEO, CFO, and Director of Palisade Bio Inc (NASDAQ:PALI), made a significant insider purchase of 15,000 shares of the company's stock. |
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq RulesCarlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the registered direct offe |
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical OfficerAnnounces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven track record of successfully developing oral biotherapeutics and locally acting immunomodulating t |
Why Is Asensus Surgical (ASXC) Stock Up 18% Today?Asensus Surgical (ASXC) stock is rising higher on Thursday as investors react to news of a collaboration with Nvidia NVDA). |
Why Is Palisade Bio (PALI) Stock Down 46% Today?Palisade Bio (PALI) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're diving into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning! |
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq RulesCarlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the registered |